What is the appropriate starting dose of dulaglutide (Trulicity) for a patient?

Starting Dose of Trulicity (Dulaglutide)

The recommended starting dose of Trulicity is 0.75 mg injected subcutaneously once weekly for both adults and pediatric patients 10 years and older. 1

Dosing Algorithm

Initial Dosing

• Start all patients at 0.75 mg once weekly, regardless of age (adults or pediatric patients ≥10 years) 1
• Administer subcutaneously in the abdomen, thigh, or upper arm
• Can be given any time of day, with or without food 1

Dose Escalation Strategy

For Adults:

• After starting at 0.75 mg, increase to 1.5 mg once weekly if additional glycemic control is needed 1
• If further control is required, escalate in 1.5 mg increments after at least 4 weeks on the current dose 1
• Maximum dose: 4.5 mg once weekly 1
• The 4-week interval between dose increases is critical to minimize gastrointestinal side effects, particularly nausea and vomiting 2

For Pediatric Patients (10 years and older):

• Start at 0.75 mg once weekly
• Maximum dose: 1.5 mg once weekly (after at least 4 weeks on 0.75 mg) 1
• Do not exceed 1.5 mg in pediatric patients

Key Clinical Considerations

Why Start at 0.75 mg?

The 0.75 mg starting dose provides effective glycemic control while minimizing gastrointestinal adverse effects. Real-world data shows that 67-70% of patients initiate at 0.75 mg 3, and this approach allows for tolerance development before escalation.

Dose Escalation Timing

Wait at least 4 weeks before increasing the dose. This interval is evidence-based: modeling studies demonstrate that 4-week intervals significantly reduce the probability of nausea and vomiting events compared to faster escalation 2. GLP-1 receptor agonist-related gastrointestinal effects are dose-dependent and attenuate with repeated dosing over time.

Real-World Dosing Patterns

In UK primary care data, many patients remain on suboptimal doses: at prescription 10, dulaglutide users were distributed as 20.4% on 0.75 mg, 71.5% on 1.5 mg, and only 6.7% on 3 mg 4. This suggests clinicians often maintain patients on lower doses, though escalation should be considered if glycemic targets are not met.

Common Pitfalls to Avoid

1. Starting too high: Do not initiate at 1.5 mg or higher doses—this increases gastrointestinal side effects without allowing tolerance development
2. Escalating too quickly: Rushing dose increases before 4 weeks increases nausea/vomiting risk 2
3. Forgetting pediatric limits: Pediatric patients should not exceed 1.5 mg weekly 1
4. Inadequate patient counseling: Patients must understand the once-weekly schedule and proper injection technique before starting 1

Special Populations

Renal Impairment

• No dose adjustment required for dulaglutide regardless of kidney function 5
• This distinguishes it from some other diabetes medications

Obesity Status

Dulaglutide is effective across all BMI categories. Post-hoc analysis of 5,770 patients showed no treatment-by-BMI interaction for HbA1c reduction 6. The starting dose remains 0.75 mg regardless of baseline weight.

Cardiovascular Disease

For patients with established CVD or multiple cardiovascular risk factors, still start at 0.75 mg. Dulaglutide has demonstrated cardiovascular benefits (MACE reduction) in the REWIND trial 7, but this does not change the starting dose recommendation.

Administration Details

• Inject once weekly on the same day each week
• If a dose is missed and ≥3 days (72 hours) remain until the next scheduled dose, administer immediately
• If <3 days remain, skip the missed dose and resume the regular schedule 1
• When used with insulin, administer as separate injections (never mix), though they can be given in the same body region if not adjacent 1